About Us

R&D Pipeline

We are initially focused ion topical AMR infections since (a)  the size of the market is so large and (b) there are virtually no other affordable solutions, either on the market or under development, to treat or prevent such infections at a reasonable cost.  However, over time, in addition to our eczema and acne treatments, we will look to in-license later stage biological dermatological treatments for some underserved indications including for the following problems: additional AMR topical solutions, oncodermatology, actinic keratosis, and/or psoriasis. As we expand we will become one of the leading skin sciences companies in China.

Management Team

Mark Engel


Previously founded 4 successful life sciences companies

Dr. Nancy Tawil 

Chief Scientific Officer

Ph.D in Biomedical Engineering and Phage Expert

Dr. Assaf Raz

Lab Manager - Wuhan

Ph.D in Biology and Leading Global Lysin Expert

Sandy Li

Quality Manager

M.S. in Chemistry. Experienced in GMP

drug production

Dr. Iness Hammami

Vice-President, Research

Ph.D in Chemical Engineering.

10 years of experience in biopharmaceutical engineering

Board Members

Edward Hu

CO-CEO of WuXi AppTec

Aaron Yu

Managing Director at

 Investment Department of Fosun Pharma

Mark Engel

CEO of Phagelux


Phagelux is a Cayman platform company, focused on China first, that utilizes phages, lysins, and novel delivery systems to create First in Class treatments for large unmet or under met skin conditions. Phagelux Targets are effectively preventing and treating AMR resistant topical infections, and difficult to treat Eczema and Acne cases. It has R&D centers in Montreal, Canada and Wuhan, China. The former is focused on bacteriophage products while the latter develops lysin products.

Phagelux has significant IP and unique knowhow. In total, 26 patents have been filed in China, US, Europe, and other key markets, and 8 patents have been issued. These include patents of preparation method and method of use. In addition, Phagelux has unique platform knowhow in phage delivery and fast high throughput lysin development systems.

Our two highly novel platforms include sustained released treatments (phage and bioengineering – first IND approved; lead product IND expected in Q1 2021) and engineered lysins (enhanced phage – first IND by mid of 2021).


Jan.16, 2020  Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.

Technical Support: 赛泊斯 | Admin Login